News Related to Cadonilimab

Related coverage linked through entity extraction aliases.

Akeso Reports Survival Benefit in Phase III Lung Cancer Trial, Enrolls First Patient in Breast Cancer Study

Jun 15, 2026

Akeso reported overall survival benefit for ivonescimab plus chemotherapy in Phase III lung cancer study. The company enrolled first patient in Phase Ib/II trial of next-generation HER3 ADC AK138D1 for advanced breast cancer. Akeso also received China approval to start Phase II trials for AK139 bispecific antibody.

Three New Glioblastoma Research Advances Target Diagnostics and Immunotherapy

Mar 10, 2026

Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.